142 results
8-K
EX-99.1
PRPO
Precipio Inc
4 Sep 20
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
4:00pm
questions from shareholders related to company COVID-19 strategy
NEW HAVEN, CT, (September 4th, 2020) - Specialty cancer diagnostics company Precipio, Inc … . (NASDAQ: PRPO), will be hosting a shareholder call to address questions related to the company's COVID-19 strategy. The call will take place
8-K
EX-99.1
PRPO
Precipio Inc
6 Nov 13
Transgenomic Reports Third Quarter 2013 Financial Results
12:00am
of a former executive, partially offset by reductions in our Laboratory Services field sales force, as we adopted our new channel strategy with partners … commercialization agreements with PerkinElmer and PDI, as recently announced, highlight our renewed vigor and corporate strategy, which aims to optimize
8-K
EX-99.1
PRPO
Precipio Inc
11 Mar 19
Precipio CEO Issues Shareholder Update Letter
4:50pm
information on three key topics:
Nasdaq compliance strategy
Capital raise philosophy
Management (insider) stock acquisition
Nasdaq Compliance … Strategy
The management team’s goal to protect and preserve shareholder value remains in focus at all times. As we face the deadline to achieve
8-K
EX-99.1
xebd4vga 4s8bucvn
7 Oct 11
Regulation FD Disclosure
12:00am
8-K
EX-99.1
9bqj6du1
18 Jul 18
Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results
4:50pm
8-K
EX-99.1
xrh3zcgase7vsxt
20 Jul 22
Agreement Enhances Precipio’s Product Reach to US Laboratories
7:16pm
8-K
EX-99.1
4rxf3 4n4rk8csby7f5
30 Sep 15
Transgenomic Signs Binding Term Sheet to Divest Genetic Assays & Platforms Business Unit
12:00am
8-K
EX-99.1
iien7 ph7
17 Sep 12
Departure of Directors or Certain Officers
12:00am